Similarly, LOXL2 is found to promote colorectal cancer [19], gastric cancer [20,21], esophageal squamous cell carcinoma [22], cholangiocarcinoma [23], hepatocellular carcinoma [24], lung squamous cell carcinoma [25], non-small cell lung cancer [26,27], and renal cell carcinoma [28], to name some examples out of the many types of cancer in which tumor progression is enhanced by LOXL2. This evidence concerns the gene LOXL2 and hereditary clear cell renal cell carcinoma.